NLM Digital Collections

Search

Start Over Subjects United States ✖Remove constraint Subjects: United States Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

291. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic -- drug therapy
Interleukin-4 Receptor alpha Subunit -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors -- therapeutic use
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Cyclosporine -- therapeutic use
Phosphodiesterase 4 Inhibitors -- adverse effects
Phototherapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

292. Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, July 17, 2017
Subject(s):
Anabolic Agents -- therapeutic use
Antibodies, Monoclonal, Humanized -- therapeutic use
Osteoporosis, Postmenopausal -- drug therapy
Parathyroid Hormone-Related Protein -- therapeutic use
Anabolic Agents -- adverse effects
Anabolic Agents -- economics
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Bone Density Conservation Agents -- adverse effects
Bone Density Conservation Agents -- economics
Bone Density Conservation Agents -- therapeutic use
Comparative Effectiveness Research
Diphosphonates -- adverse effects
Diphosphonates -- economics
Diphosphonates -- therapeutic use
Osteoporotic Fractures -- prevention & control
Parathyroid Hormone-Related Protein -- adverse effects
Parathyroid Hormone-Related Protein -- economics
Randomized Controlled Trials as Topic
Teriparatide -- adverse effects
Teriparatide -- economics
Teriparatide -- therapeutic use
Humans
United States

293. Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
Subject(s):
Abuse-Deterrent Formulations -- economics
Abuse-Deterrent Formulations -- statistics & numerical data
Analgesics, Opioid -- economics
Analgesics, Opioid -- therapeutic use
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- prevention & control
Prescription Drug Diversion -- statistics & numerical data
Comparative Effectiveness Research
Cost-Benefit Analysis
Delayed-Action Preparations -- economics
Delayed-Action Preparations -- therapeutic use
Drug Compounding -- economics
Drug Overdose -- mortality
Insurance Coverage -- economics
Insurance, Pharmaceutical Services -- economics
Opioid-Related Disorders -- epidemiology
Humans
United States

294. Poly ADP-ribose polymerase (PARP) inhibitors for ovarian cancer: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, September 28, 2017
Subject(s):
Ovarian Neoplasms -- drug therapy
Poly(ADP-ribose) Polymerase Inhibitors -- therapeutic use
Comparative Effectiveness Research
Poly(ADP-ribose) Polymerase Inhibitors -- adverse effects
Poly(ADP-ribose) Polymerase Inhibitors -- economics
Treatment Outcome
Humans
United States

295. Cognitive and mind-body therapies for chronic low back and neck pain: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, November 6, 2017
Subject(s):
Chronic Pain -- therapy
Cognitive Therapy
Low Back Pain -- therapy
Mind-Body Therapies
Neck Pain -- therapy
Acupuncture Therapy -- economics
Comparative Effectiveness Research
Mindfulness -- economics
Tai Ji -- economics
Treatment Outcome
Yoga
Humans
United States

296. Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 22, 2017
Subject(s):
Membrane Transport Modulators -- therapeutic use
Tardive Dyskinesia -- drug therapy
Vesicular Monoamine Transport Proteins -- antagonists & inhibitors
Antipsychotic Agents -- adverse effects
Comparative Effectiveness Research
Membrane Transport Modulators -- adverse effects
Membrane Transport Modulators -- economics
Tardive Dyskinesia -- chemically induced
Humans
United States

297. Challenges and joys: pediatricians reflect on caring for children with special health care needs

Author(s):
Calvin, Kris, author
Okumura, Megumi , author
Knauer, Heather, author
Publication:
Palo Alto, CA : Lucile Packard Foundation for Children's Health, March 2017
Subject(s):
Child Health Services
Disabled Children
Patient-Centered Care
Pediatrics
Physician-Patient Relations
Caregivers
Child
Electronic Health Records
Insurance, Health
Insurance, Health, Reimbursement
Patient Care Team
Primary Health Care
Social Support
Humans
California
United States

298. Survey: quantifying pediatricians' views on caring for children with special health care needs

Author(s):
Calvin, Kris, author
Okumura, Megumi, author
Knauer, Heather, author
Publication:
Palo Alto, CA : Lucile Packard Foundation for Children's Health, March 2017
Subject(s):
Child Health Services
Disabled Children
Health Services Needs and Demand
Pediatrics
Primary Health Care
Child
Health Services Accessibility
Insurance, Health, Reimbursement
Patient Care Team
Patient-Centered Care
Humans
California
United States

300. Recommendations to improve access to mental health services for children with special health care needs in California

Author(s):
Coursolle, Abbi, author
Lewis, Kim, author
Publication:
Palo Alto, CA : Lucile Packard Foundation for Children's Health, June 2017
Subject(s):
Child Health Services
Disabled Children
Health Services Accessibility
Health Services Needs and Demand
Mental Disorders -- therapy
Mental Health Services
Child
Insurance Coverage
Medicaid
Humans
California
United States